SCHEMBL13904802

SCHEMBL13904802

CC(C)C[C@@H](C(=O)N[C@H]1N=C(c2ccccc2F)c2ccccc2N(C(C)C)C1=O)C1(C(N)=O)CC=CC1

nearest known ligand 0.44

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
NOTCH1 P46531 2/20 0.44
NOTCH3 Q9UM47 1/20 0.44
PSEN1 P49768 1/20 0.43
PSEN2 P49810 1/20 0.43
RBPJ Q06330 1/20 0.43
APH1B Q8WW43 1/20 0.43
NCSTN Q92542 1/20 0.43
APH1A Q96BI3 1/20 0.43
PSENEN Q9NZ42 1/20 0.43
CCKAR P32238 14/20 0.42
CCKBR P32239 14/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13904798 1.00 NOTCH1 (0.44) NOTCH1NOTCH3PSEN1PSEN2RBPJ
SCHEMBL4147285 1.00 NOTCH1 (0.44) NOTCH1NOTCH3PSEN1PSEN2RBPJ
SCHEMBL14025959 0.90 NOTCH1 (0.44) NOTCH1NOTCH3PSEN1PSEN2RBPJ
SCHEMBL14025958 0.90 NOTCH1 (0.44) NOTCH1NOTCH3PSEN1PSEN2RBPJ
SCHEMBL13904804 0.90 CCKBR (0.45) NOTCH1NOTCH3PSEN1PSEN2RBPJ
SCHEMBL4160293 0.90 CCKBR (0.45) NOTCH1NOTCH3PSEN1PSEN2RBPJ
SCHEMBL4151394 0.86 NOTCH1 (0.45) NOTCH1PSEN1PSEN2RBPJAPH1B
SCHEMBL13904805 0.86 NOTCH1 (0.45) NOTCH1PSEN1PSEN2RBPJAPH1B
SCHEMBL4159022 0.81 NOTCH1 (0.65) NOTCH1NOTCH3PSEN1PSEN2RBPJ
SCHEMBL13904669 0.81 NOTCH1 (0.65) NOTCH1NOTCH3PSEN1PSEN2RBPJ

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090062256-A1 LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2009-03-05 US disclosed
US-20090062256-A1 LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2009-03-05 US disclosed
US-7456278-B2 Lactams substituted by cyclic succinates as inhibitors of Aβ protein production BRISTOL-MYERS SQUIBB PHARMA CORPORATION (US) 2008-11-25 US disclosed
US-7456278-B2 Lactams substituted by cyclic succinates as inhibitors of Aβ protein production BRISTOL-MYERS SQUIBB PHARMA CORPORATION (US) 2008-11-25 US disclosed
US-20080103128-A1 LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF ABETTA PROTEIN PRODUCTION BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2008-05-01 US disclosed
US-20080103128-A1 LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF ABETTA PROTEIN PRODUCTION BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2008-05-01 US disclosed
US-7354914-B2 Lactams substituted by cyclic succinates as inhibitors of Aβ protein production BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2008-04-08 US disclosed
US-7354914-B2 Lactams substituted by cyclic succinates as inhibitors of Aβ protein production BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2008-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090062256-A1 LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION BACE1, APP, APH1A NOTCH1 166/4885NOTCH3 518/4885PSEN1 5/4885
US-20080103128-A1 LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF ABETTA PROTEIN PRODUCTION APH1A, APH1B, APP NOTCH1 488/4885NOTCH3 744/4885PSEN1 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.